Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities

被引：22

作者：

Boucle, Sebastien ^{[1
]}

Bassit, Leda ^{[1
]}

Ehteshami, Maryam ^{[1
]}

Schinazi, Raymond F. ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Ctr AIDS Res, Lab Biochem Pharmacol,Dept Pediat, Atlanta, GA 30322 USA

来源：

CLINICS IN LIVER DISEASE | 2016年 / 20卷 / 04期

关键词：

HBV cure; siRNA; CRISPR/Cas9; Anti-HBV agents; cccDNA; HBsAg; Antiviral therapy; CIRCULAR DNA FORMATION; HBV REPLICATION; ENTRY INHIBITOR; MYRCLUDEX-B; LIFE-CYCLE; IN-VITRO; THERAPIES; COMPOUND; RESISTANT; INFECTION;

D O I：

10.1016/j.cld.2016.07.001

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

Hepatitis B virus (HBV) causes significant morbidity and mortality worldwide. The majority of chronically infected individuals do not achieve a functional and complete cure. Treated persons who achieve a long-term sustained virologic response (undetectable HBV DNA), are still at high risk of developing morbidity and mortality from liver complications. This review focuses on novel, mechanistically diverse anti-HBV therapeutic strategies currently in development or in clinical evaluation, and highlights new combination strategies that may contribute to full elimination of HBV DNA and covalently closed circular DNA from the infected liver, leading to a complete cure of chronic hepatitis B.

引用

页码：737 / +

页数：14

共 47 条

[1]

Effects of nucleic acid polymer therapy alone or in combination with immunotherapy on the establishment of SVR in patients with chronic HBV infection [J].